 |
| John Brooks |
Gatineau's ImaSight Corp. (TSX-V:IAS), freshly opened as a public company, announced red-ink financial results Thursday while trumpeting news of new distributors for its veterinary digital X-ray sensors.
Colorado-based Apexx Equipment, which already uses the ImaSight 4600 sensor for veterinary medicine, will join with Mississauga's CAN-med Healthcare to parcel out the sensor to vendors.
ImaSight also heralded the sale of a second sensor – the Digital VetTek x-ray system – to a major, unnamed veterinary hospital chain in North America. AFP Imaging of New York will handle distribution for VetTek.
The company's financial results showed a comprehensive and net loss of $1.03 million in the eight months leading up to June 30.
ImaSight's gross profit was $237,297 and its sales reached $574,387 during the same time period.
Earlier this month, ImaSight CEO John Brooks said the company may sell off the CRD-5 drug technology it acquired through a reverse takeover of Liponex Inc.
The drug treats heart disease by raising 'good cholesterol' - also known as high-density lipoprotein or HDL - levels in the body.
* To print this page, click on the "Printer Friendly Version" link above. When the new
window opens, right-click with your mouse in the new window and select "Print".
